Micronutrient monitoring: which panel, how often, and on whose evidence

What does apply is reduced intake. Somebody eating forty per cent less food is consuming forty per cent fewer micronutrients, and a diet already marginal in iron or B12 becomes clearly inadequate. That is a real mechanism and it predicts a different pattern from the bariatric one: deficiencies proportional to dietary quality rather than to the specific nutrients whose absorption sites were bypassed. The Journal has found no cohort study characterising micronutrient status in this population at any duration, which means the incidence is unknown and any monitoring schedule is a precaution rather than a protocol.

Why the transaminases fall

The fall in alanine aminotransferase during successful treatment is one of the few laboratory movements in this field with a directly demonstrated mechanism, because liver fat was measured by imaging in several programmes rather than inferred from enzymes. A trial of semaglutide in biopsy-confirmed steatohepatitis reported resolution of steatohepatitis without worsening of fibrosis in a substantially greater proportion of treated participants than placebo, with corresponding falls in transaminases.¹ The larger phase 3 programme in the same indication subsequently reported histological improvement on both resolution and fibrosis endpoints.²

Alongside that sits the imaging evidence from the diabetes programme, where liver fat content measured by magnetic resonance fell considerably more on a dual agonist than on insulin at broadly comparable glycaemic control, which separates the hepatic effect from the glycaemic one.

What this establishes is that the falling ALT is tracking a real change in the liver rather than reflecting reduced enzyme release for some incidental reason. What it does not establish is how much of the change is attributable to the weight loss and how much to a direct hepatic effect, since the two are not separable in a trial where the treated arm also lost more weight.

The acute-phase reactants move together

C-reactive protein falls substantially during successful weight loss on these agents, with reductions of the order of a third to a half reported in the obesity programmes, and it fell on treatment in the cardiovascular outcome trial in overweight and obesity without diabetes as well.³ Ferritin, fibrinogen and several other acute-phase proteins move in the same direction for the same reason: adipose tissue is an inflammatory organ and there is less of it.

The interpretive trap is ferritin. It is used clinically as a marker of iron stores and it is also an acute-phase reactant, which means it is raised by inflammation independently of iron. A person whose ferritin falls from 140 to 55 during a year of treatment may have depleted their iron stores on a reduced intake, or may have had a falsely reassuring ferritin all along that is now revealing a pre-existing deficiency, or may simply have less inflammation. Transferrin saturation and, where necessary, soluble transferrin receptor distinguish these; ferritin alone does not.

The same logic applies in reverse to any marker that is suppressed by inflammation. The Journal reports these movements as a group because reading them individually is how the mistakes happen: three or four analytes moving together during weight loss is a single physiological story, and treating it as three or four findings multiplies the investigation without adding to the information.

Thyroid function during energy restriction

Sustained energy restriction produces a characteristic and benign change in thyroid function tests: triiodothyronine falls, reverse triiodothyronine rises, thyroxine changes little and thyroid-stimulating hormone falls modestly or remains unchanged. This is the low-T3 pattern of adaptation to reduced energy availability, it is not hypothyroidism, and treating it as such is an error that predates this drug class by decades.

The relevant point for monitoring is that a thyroid panel drawn during rapid weight loss will frequently show a low or low-normal free T3, and that this does not indicate thyroid disease, does not require treatment, and reverses when energy balance is restored. Thyroid-stimulating hormone remains the appropriate first-line test for suspected thyroid dysfunction; adding free T3 to a panel during active weight loss reliably generates a result that requires explaining.

Separately and unrelatedly, this class carries a boxed warning in some jurisdictions derived from rodent thyroid C-cell findings. Serum calcitonin monitoring is not recommended for that purpose, and pharmacoepidemiological work examining thyroid cancer incidence in treated populations has not established the association the rodent data raised as a possibility.⁴ The Journal reports the boxed warning as what it is: a precaution derived from a rodent finding whose human relevance remains unestablished.

The bariatric schedule and how far it transfers

Post-bariatric micronutrient surveillance is well founded and specific. Roux-en-Y gastric bypass bypasses the duodenum and proximal jejunum, which are the principal absorption sites for iron, calcium and several B vitamins; reduced gastric acid impairs the release of food-bound B12 and the reduction of ferric iron; and the intrinsic-factor pathway is compromised by the reduction in parietal cell mass. Each of those is an identified mechanism supporting a specific test at a specific interval.

None of them applies to a receptor agonist. The gastrointestinal tract is anatomically intact, acid secretion is broadly preserved, and no absorption site is bypassed. The mechanism that does apply is reduced intake, which predicts deficiency in proportion to dietary inadequacy rather than in the bariatric pattern. Those two predictions differ: a person eating half as much of a varied diet is at different risk from a person whose duodenum has been bypassed, and the appropriate surveillance is not obviously the same.

The Journal has looked for a cohort study characterising micronutrient status in this population at twelve months or beyond and has not found one. Until one exists, monitoring schedules for this drug class are precautionary extrapolation. That is a defensible thing to do and it should be described accurately rather than presented as protocol.

Four markers with specific confounders

Vitamin D. Concentrations frequently rise during weight loss for a reason unrelated to intake: the vitamin is fat-soluble and distributes into adipose tissue, so a smaller adipose compartment produces a higher serum concentration at unchanged total body content. A rising 25-hydroxyvitamin D during weight loss is therefore a volume-of-distribution effect as much as anything else.

Vitamin B12. The commonest confounder is co-prescription of metformin, which lowers B12 by a well-established mechanism, in a population where metformin is extremely common. Attributing a low B12 to reduced intake when the person has been on metformin for eight years is a sequencing error rather than a laboratory one.

Thiamine. The one micronutrient where the Journal thinks the precaution is well founded on mechanism: thiamine stores are small, turnover is rapid, and protracted vomiting is a recognised precipitant of deficiency. Prolonged vomiting during escalation is a plausible route to it.

Magnesium and potassium. Both fall with persistent vomiting and both are genuine findings when they do. Neither is a nutritional marker in that context; they are consequences of the losses.

Against measuring too often

Frequent monitoring in a person doing well is a reliable generator of work. Each comprehensive panel carries a substantial probability of at least one flagged result; the flags are mostly noise; each requires explanation, repetition or investigation; and the cumulative effect over a year of monthly panels is several investigations and no additional information about the person.

There is also a specific problem with monitoring an analyte more frequently than its own window. HbA1c integrates three months. Measuring it monthly produces overlapping windows in which two-thirds of the data is shared between consecutive results, so the apparent trend is smoother than the underlying glycaemia and the independent information per measurement is low. The trials in this class scheduled it quarterly for exactly this reason.

The counter-argument deserves stating fairly: monitoring during escalation, when tolerability problems and their metabolic consequences are most likely, is a different proposition from monitoring during stable maintenance, and the case for closer observation in the first three months is reasonable. What the Journal has not seen is any evidence that a fixed frequent schedule during maintenance detects anything that a symptom-prompted panel would miss. Readers who know of such evidence should write to standards@compoundjournal.com.

Analytical testing and clinical testing are different activities

A distinction has to be drawn firmly because the postbag suggests it frequently is not. The four independent testing services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — analyse material. They report chromatographic purity, identity by mass, peptide content where it is measured, and in the case of the verification services what could be established about a supplier. A clinical laboratory analyses a person. The two produce documents that superficially resemble each other and answer entirely unrelated questions.

A purity certificate reporting 99.1 per cent for a batch from WWB, CPC or QYB tells you nothing about anybody liver enzymes. A normal panel does not confirm that a vial contained what its label claimed, and an abnormal one does not establish that it did not. Where a person suspects a supply problem, the instrument for that is analytical testing of the material; where a person has an abnormal laboratory result, the instrument is clinical assessment. Substituting one for the other is a reliable way to spend money and learn nothing.

Compounds sold for research use only are not approved for human use in any jurisdiction, and nothing in this department should be read as guidance about using them or about monitoring their use.

How the Journal reports a laboratory figure

Five things accompany a laboratory number in these pages. The units, because international and conventional units differ for several analytes and the same value means different things in each. The reference interval used, with a note where the interval is contested, as it is for alanine aminotransferase. The baseline, because a change of 1.8 percentage points in HbA1c from a starting value of 8.3 is a different claim from the same change from 9.5. The estimand where the figure comes from a trial. And the reference change value where we are discussing an individual delta rather than a group mean.

We also state the assay method where it matters, which is more often than one would like: HbA1c in the presence of a haemoglobin variant, thyroid function in the presence of interfering antibodies, and creatinine measured by enzymatic against Jaffe methods all behave differently, and a comparison across methods is not a comparison.

This is a heavier apparatus than most publications carry and it exists because the alternative, in our experience, is a stream of technically accurate figures that lead readers to conclusions the data does not support. Errors in this apparatus should be reported to standards@compoundjournal.com; the correction log records what came of each one.

What this department is for

The Laboratory Notebook reports what tests measure, how they behave, and what has been found using them. It does not recommend monitoring schedules, interpret readers’ results, or advise on treatment. A laboratory result belongs in a conversation with a clinician who has the rest of the picture, and this publication is emphatically not that conversation.

Two standing notes. Several compounds discussed in these pages are sold for research use only and are not approved for human use in any jurisdiction; the Journal reports on them as commodities and as analytical problems, not as therapies. And where we describe what the pivotal trials monitored, that is reporting on trial protocols and not a template anybody should adopt from a magazine.

Correspondence is welcome at letters@compoundjournal.com. The Journal receives a steady flow of letters containing readers’ own panel results with a request for interpretation, and we do not provide it — not from caution but because a panel without a history, an examination and a reason for ordering it cannot be interpreted by anybody, including us.

Three artefacts recur often enough to be worth committing to memory. Creatinine falls because muscle mass falls, so estimated kidney function rises for a reason that has nothing to do with kidneys. Free triiodothyronine falls because energy intake fell, and that is adaptation rather than disease. And ferritin falls because inflammation falls, which may or may not coincide with iron stores falling. None of these is obscure and all three are routinely acted upon.